JP2008515889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515889A5 JP2008515889A5 JP2007535700A JP2007535700A JP2008515889A5 JP 2008515889 A5 JP2008515889 A5 JP 2008515889A5 JP 2007535700 A JP2007535700 A JP 2007535700A JP 2007535700 A JP2007535700 A JP 2007535700A JP 2008515889 A5 JP2008515889 A5 JP 2008515889A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- xaa
- conjugate molecule
- cys
- sabm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 108010052285 Membrane Proteins Proteins 0.000 claims 4
- 102000018697 Membrane Proteins Human genes 0.000 claims 4
- 102000007562 Serum Albumin Human genes 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 239000003145 cytotoxic factor Substances 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002458 cell surface marker Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229920002776 polycyclohexyl methacrylate Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61650704P | 2004-10-05 | 2004-10-05 | |
| US64153405P | 2005-01-05 | 2005-01-05 | |
| PCT/US2005/033952 WO2006041641A2 (en) | 2004-10-05 | 2005-09-22 | Therapeutic agents with decreased toxicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008515889A JP2008515889A (ja) | 2008-05-15 |
| JP2008515889A5 true JP2008515889A5 (enExample) | 2008-11-13 |
Family
ID=36051453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007535700A Withdrawn JP2008515889A (ja) | 2004-10-05 | 2005-09-22 | 毒性の低下した治療剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20060073152A1 (enExample) |
| EP (1) | EP1796718A2 (enExample) |
| JP (1) | JP2008515889A (enExample) |
| KR (1) | KR20070073886A (enExample) |
| AU (1) | AU2005294723A1 (enExample) |
| BR (1) | BRPI0516577A (enExample) |
| CA (1) | CA2583137A1 (enExample) |
| IL (1) | IL182261A0 (enExample) |
| MX (1) | MX2007003907A (enExample) |
| RU (1) | RU2007116973A (enExample) |
| WO (1) | WO2006041641A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| EP1817336B1 (en) * | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| ES2585357T3 (es) | 2005-07-07 | 2016-10-05 | Seattle Genetics, Inc. | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| US8871720B2 (en) * | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| CL2008002085A1 (es) | 2007-07-16 | 2008-11-21 | Genentech Inc | Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b |
| EP2641618A3 (en) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
| US20090035848A1 (en) * | 2007-08-03 | 2009-02-05 | Robert Hickey | Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products |
| CN104650230A (zh) | 2008-01-31 | 2015-05-27 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
| CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
| EP2513148B1 (en) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
| CA2833477A1 (en) * | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| US20140127713A1 (en) | 2011-06-28 | 2014-05-08 | Femke Karina de Theije | Means for the examination of body fluids |
| WO2013096940A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Double binding constructs |
| EP3013370A1 (en) * | 2013-06-24 | 2016-05-04 | Riogin Corporation | Double binding constructs |
| DK3039038T3 (da) * | 2013-08-30 | 2021-02-08 | Aprilbio Co Ltd | Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil |
| EP3262071B8 (en) | 2014-09-23 | 2022-05-18 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| EP3665202A1 (en) * | 2017-08-09 | 2020-06-17 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2023092733A1 (zh) * | 2021-11-25 | 2023-06-01 | 苏州慧疗生物医药科技有限公司 | 一种用于有效递送核酸的环状多肽载体及其变化形式 |
| EP4592321A1 (en) * | 2022-09-20 | 2025-07-30 | Biotheus Inc. | Anti-her2 antibodies and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3561444A (en) * | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
| US3703173A (en) * | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
| US3862925A (en) * | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) * | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (enExample) * | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) * | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4635627A (en) * | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
| US4624251A (en) * | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
| US4970198A (en) * | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| EP0940468A1 (en) * | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE69226197T2 (de) * | 1991-11-08 | 1999-02-11 | Somatogen, Inc., Boulder | Hämoglobine als arzneimittelabgabesystem |
| US5767237A (en) * | 1993-10-01 | 1998-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Peptide derivatives |
| US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5780054A (en) * | 1996-01-17 | 1998-07-14 | University Of British Columbia | Methods for increasing the circulation half-life of protein-based therapeutics |
| US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20030009395A1 (en) * | 2001-07-06 | 2003-01-09 | Yu Philip Shi-Lung | Method and apparatus for providing information regarding a product |
| ES2411007T3 (es) * | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7435797B2 (en) * | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| WO2004032828A2 (en) * | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| US20040032828A1 (en) * | 2002-08-16 | 2004-02-19 | Cellglide Technologies Corp. | Service management in cellular networks |
| BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
-
2005
- 2005-09-22 KR KR1020077010255A patent/KR20070073886A/ko not_active Withdrawn
- 2005-09-22 MX MX2007003907A patent/MX2007003907A/es not_active Application Discontinuation
- 2005-09-22 BR BRPI0516577-6A patent/BRPI0516577A/pt not_active Application Discontinuation
- 2005-09-22 EP EP05810079A patent/EP1796718A2/en not_active Withdrawn
- 2005-09-22 CA CA002583137A patent/CA2583137A1/en not_active Abandoned
- 2005-09-22 AU AU2005294723A patent/AU2005294723A1/en not_active Abandoned
- 2005-09-22 JP JP2007535700A patent/JP2008515889A/ja not_active Withdrawn
- 2005-09-22 WO PCT/US2005/033952 patent/WO2006041641A2/en not_active Ceased
- 2005-09-22 US US11/233,256 patent/US20060073152A1/en not_active Abandoned
- 2005-09-22 RU RU2007116973/13A patent/RU2007116973A/ru not_active Application Discontinuation
-
2006
- 2006-09-25 US US11/535,027 patent/US20090123376A1/en not_active Abandoned
-
2007
- 2007-03-28 IL IL182261A patent/IL182261A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515889A5 (enExample) | ||
| JP7133611B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| JP7244987B2 (ja) | 多剤抗体薬物コンジュゲート | |
| JP2024096335A (ja) | 親水性抗体－薬物コンジュゲート | |
| RU2007116973A (ru) | Терапевтические средства с пониженной токсичностью | |
| JP2023089195A (ja) | グリピカン３抗体およびそのコンジュゲート | |
| CN112601522B (zh) | 抗体-alk5抑制剂偶联物及其用途 | |
| JP2023520930A (ja) | 電荷多様性リンカー | |
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| TW201709932A (zh) | Ｃｄ１２３抗體及其共軛物 | |
| JP2015509097A5 (enExample) | ||
| JP2013173792A (ja) | 増強された薬理学的性質を有する活性物質を送達するための方法および組成物 | |
| KR20160113623A (ko) | 항체-약물 접합체 및 면역독소 | |
| JP2022547434A (ja) | 標的化デンドリマー複合体 | |
| JPWO2020188061A5 (enExample) | ||
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| JP2023529640A (ja) | 治療用コンジュゲート | |
| JP2024528496A (ja) | ウロキナーゼ型プラスミノーゲン活性化因子受容体関連タンパク質（ｕｐａｒａｐ）を標的とするヒト化抗体を含む、抗体薬物複合体 | |
| Hui et al. | An innovative site-specific anti-HER2 antibody-drug conjugate with high homogeneity and improved therapeutic index | |
| CA2862292C (en) | Binding molecule conjugates | |
| JP2024542021A (ja) | ペイロードのｉｎ ｖｉｖｏ標的化送達用のテトラジンコンジュゲート | |
| CN115052663A (zh) | Alk5抑制剂缀合物及其用途 | |
| CN114269388A (zh) | 抗体-alk5抑制剂缀合物及其用途 | |
| CN101277716A (zh) | 治疗癌症的抗体 |